Cholecystolithiasis – a practical approach from the endosonographer

D. O’Toole, L. Palazzo
Service de Gastroentérologie, Hôpital Beaujon, Clichy 92118, Beaujon Hospital, University of Paris VII, Clichy, France

Introduction

The widespread availability of endoscopic ultrasound (EUS) has facilitated evaluation of the pancreas and extra-hepatic biliary system. EUS to date has been shown to be highly sensitive in the detection of both cholecystolithiasis (especially in patients with small stones and non-dilated bile ducts) and gallbladder microlithiasis, however the use of this technique in relation to endoscopic retrograde cholangiography (ERCP) and laparoscopic surgery in gallstone disease remains somewhat confusing. EUS has the added advantage of accurately discriminating CBD obstruction due to cholecystolithiasis and other causes such as small ampullary tumours, cholangiocarcinoma, benign extra-hepatic cholangitis, congenital bile duct or peri-ampullary abnormalities (which together account for 10–20% of cases of CBD obstruction in patients with suspicion of CBD stones). This review highlights technical aspects of examining the extra-hepatic biliary duct system and the clinical performance and results of EUS in this context and proposes strategies in relation to its use in association with ERCP and surgery in common clinical practice. The use of EUS in patients with a symptomatic dilated common bile duct (CBD) is also discussed.

Technical aspects

Visualisation of the extra-hepatic bile ducts using EUS demands a systematic approach and is best performed under mild intravenous sedation with midazolam and/or propofol. With the patient in the left lateral decubitus position the transducer is placed in the distal portion of the second segment of the duodenum and withdrawn to the ampullary region. Above the distal common bile duct (CBD) is seen along with the terminal portion of the main pancreatic duct (Fig. 1). Slight proximal movements allow visualisation of the intra-pancreatic CBD which is often located close to water balloon; the latter may sometimes need to be deflated so as to not compress the CBD (Fig. 1a). The CBD and common hepatic duct (CHD) are examined in longitudinal sections (Fig. 2) as far proximally as the hepatic duct with the transducer in the genu superius and/or the duodenal bulb. The proximal duodenum also affords examination of the porta hepaticus with the cystic duct and the fundus and neck of the gallbladder. Positioning in the duodenal bulb yields access to the gallbladder and CBD from its origin in the hilum to the convergence of cystic and hepatic ducts and the proximal portion of the CBD (Fig. 5a). Using this method, the hepatic duct and CBD can be visualized in 95–100% of patients [1–4]. It is also mandatory to examine the gall bladder fundus via the transgastric route with the transducer in the gastric antrum.

Standard imaging frequencies of 7.5 and 12 MHz are employed allowing resolution to 1 mm thus allowing for the detection of very small stones – microlithiasis. However, it is important to start with a lower frequency to ensure that biliary disease at a distance from the transducer is not missed. Slight repositioning of the patient in the semi-prone position may be required to bring the CBD in line with the ultrasound field of view. While it is sometimes difficult to examine the CHD at the level of the hepatic hilum, especially using radial instruments, use of linear scopes facilitates longitudinal views at this level. Another not infrequent, difficulty occurs following endoscopic sphincterotomy or choledochoduodenostomy, where the presence of air within the CBD makes it difficult to examine the peri-ampullary region and CHD, respectively.

Performance of EUS in the detection of cholecystolithiasis

In a prospective and competitive blinded study in a group of patients with CBD obstruction the accuracy of EUS in the diagnosis cholecystolithiasis was 100% (Figs. 3, 4) [1]. Moreover, endosonography was significantly more sensitive than transabdominal ultrasonography (US) or CT [1]. The diagnostic performance of EUS for cholecystolithiasis is summarized in Table 1 [5–11]. Data from these largely prospective studies include a large number of patients (n = 1470). EUS demonstrated a high sensitivity (a mean of 93%) with an excellent specificity level (> 95%) in these patients (Table 1) who globally, with the exception of one series [8], presented an intermediate risk of CBD stones (20–50%). The performance of EUS in recognising cholecystolithiasis is not related to stone size or the diameter of the CBD (Figs. 3, 4) [5, 9] and high degrees of accuracy are also achieved with linear EUS [12]. In addition, the learning curve required to obtain satisfactory results in diagnosing cholecystolithiasis is relatively short as physicians with less than 1 years experience achieve a high degree of skill in this indication [13].

Several studies have compared EUS and ERCP in a blinded fashion (ERCP performed subsequent to EUS and by two different operators [14,6,10]). The sensitivity of ERCP was found to be 79–90% compared to 88–100% for EUS and false-negative results were observed more frequently with ERCP. It is important to note that the false-negative results with ERCP were due to small stones located within dilated bile ducts, whereas false-negatives for EUS consisted of stones located in the proximal portion of the CBD or the intra-hepatic ducts during the examination. The excellent specificity for EUS in cholecystolithiasis has also been shown by Napoleon et al. in patients with suspected CBD stones [15] where 238 patients who were stone-free at EUS were prospectively followed at 1 year. Follow-up revealed that 97% of patients remained free of CBD stones thus demonstrating the high negative predictive value of EUS [15].

In patients with unexplained acute pancreatitis the use of EUS with high resolution affords an increased chance of detecting microlithiasis – a frequent cause of pancreatitis [16–19]. Here, the role of EUS in relation to ERCP, which is both a diagnostic and

Correspondence: Laurent Palazzo (MD) - 30, rue d’Astorg · 75008 Paris · France · Phone: 0033 1 47 42 15 51 · E-mail: laurent.palazzo@wanadoo.fr

therapeutic procedure, is under discussion. Three studies emphasized that EUS should replace ERCP as the first procedure in patients with mild to moderate acute pancreatitis to avoid unnecessary ERCP and thus diminish ERCP-induced morbidity [17–19, 20]. One interesting study devoted to this situation suggested that the rate of morbidity and mortality could be reduced by systematically using EUS in case of acute pancreatitis followed by ERCP with sphincterotomy when EUS has demonstrated CBD stones [21]. The efficacy and safety of EUS in this indication was confirmed [22] in a prospective randomized study in 140 patients with acute pancreatitis of a suspected biliary origin. Patients were randomised to EUS or ERCP within 24 hours from admission. When EUS detected cholelithiasis (EUS group), therapeutic ERCP was performed during the same endoscopy session. EUS was successful in all patients in the EUS group, whereas cannulation of the CBD during ERCP was unsuccessful in 10 patients (14%) in the ERCP group (P = 0.001). Combined percutaneous transabdominal US and ERCP failed to detect CBD stones in 6 patients in the ERCP group and overall morbidity rate was 7% and 14% (NS) in the EUS and ERCP groups, respectively [22]. Given the efficacy and relative simplicity of EUS in patients with pancreatitis of suspected biliary origin, it should be proposed as a screening method especially patients with low to moderate risks of a biliary origin. The combination of EUS and eventually ERCP, in the event of finding a CBD stone, during the same session is highly recommended to avoid a subsequent endoscopic session. Whether MRC will become sufficiently accurate for the detection of small stones in this setting remains to be shown.

**EUS or magnetic resonance cholangiography?**

The use of non-invasive techniques to detect CBD stones is an appealing option and magnetic resonance cholangiography (MRC) is gaining experience in this indication. MRC is especially interesting in patients with low to intermediate risk of choledocholithiasis (and in those who pose contraindications for sedation endoscopy) where interventional strategies are less likely to be required. However, patients with such risk for CBD stones are more likely to have small stones which may be difficult to detect without EUS (the risk groups for CBD stones are given in Table 2). Good comparative data on accuracy of MRC in the detection of choledocholithiasis are to date lacking. A high sensitivity of 100% with a lower specificity of 73% were initially reported using MRC [23] and this was reported to be independent of stone size. However, in a recent study by Kondo et al the sensitivities of EUS, MRC, and CT scan were 100%, 88%, and 88%, respectively [24]. The differences between EUS and MRC were largely explained by stone size as the sensitivity of MRC in detecting stones above and below 5 mm was 100% and 67%, respectively [24].

**Performance of EUS in the detection of gallbladder microlithiasis**

EUS is also excellent in the diagnosis of unrecognised gallbladder microlithiasis with a sensitivity of almost 100%. In patients with a high suspicion of cholelithiasis following two negative transabdominal ultrasounds EUS is the diagnostic tool of choice. The
obtained with microscopic examination of aspirated duodenal bile following stimulation by cholecystokinin (Fig. 5) [25]. These results have been subsequently confirmed [26]. Indeed in a recent multicentre prospective study involving 213 patients with acute pancreatitis endosonography was the sole method establishing the diagnosis of biliary pancreatitis in 15% of patients [27].

**EUS prior to laparoscopic cholecystectomy**

The prediction of CBD stones in patients with symptomatic cholelithiasis may be estimated with excellent precision by

---

**Fig. 1** a Longitudinal section of the common bile duct inside the pancreas with the cystic duct junction proximally and the MPD distally. b Junction of the common bile duct (CBD) and the main pancreatic duct (MPD) at the level of the ampulla of Vater.

**Fig. 2** The transducer is in the duodenal bulb and the common hepatic duct (HD) is visualised below the inflated balloon and the cystic duct junction below the hepatic duct. IVC: inferior vena cava.

**Fig. 3** a Small stone (3 mm) with typical acoustic shadowing (black arrow) in the distal portion of a non-dilated CBD. PV = portal vein. b Small stone (5 mm) within a dilated CBD (18 mm). c Three very small calculi (1 mm in size) located within the dependant portion of the lower part of the CBD which is not dilated (5 mm).
combining a number of clinical, biological and morphological criteria [28,29]. Three different risk groups may be determined (Table 2) with risk of finding choledocholithiasis of between 2 to 80%. The probability of finding stones in the CBD of these patients decreases as the period between the onset of symptoms and exploration increases because of spontaneous evacuation of CBD stones. Spontaneous evacuation of CBD stones was estimated to be approximately 21% as evaluated by EUS and ERCP performed between 6 hours and 27 days, respectively following the onset of symptoms [30]. The spontaneous passage of stones occurred in two-thirds of patients between a period of 6 hours and 3 days but stone migration continued up to 27 days following initial EUS [30]. Thus, even in patients with predictive factors suggesting a high risk of CBD stones, not all have choledocholithiasis at examination cholecystectomy [31]. The delay between symptom onset and exploration should therefore be considered in analysis of patients at risk of CBD stones as the further the delay, the lower the chance of positive results.

It is accepted that patients categorized to the different risk groups (Table 2) merit different therapeutic strategies (Table 2 and treatment algorithm). In fact, treatment options also depend on local experience of both surgeons and endoscopists and the wishes of the patients; once the advantages, risks and probabilities of success of the different methods have been clearly explained to them [32]:

- Patients in the low-risk group may be treated using laparoscopic cholecystectomy without any preoperative examination of the CBD. It seems unreasonable to propose 100 explorations (of whatever kind) of the CBD in order to identify stones in 2 or 3 patients. Some surgeons carry out systematic intra-operative opacification in order to examine the anatomy of the biliary tree and/or to verify a patent CBD.

- Those with a clearly identified high-risk may be selected at the outset for cholecystectomy using classical laparotomy. This is rarely indicated when the diagnosis of choledocholithiasis is certain following trans-abdominal ultrasound, and when the surgeon is not skilled in laparoscopic extraction of CBD stones and the patient is young and/or does not wish to have an endoscopic sphincterotomy. Endoscopic retrograde opacification may be performed for diagnosis and treatment in the presence of acute ascending cholangitis or in the case of severe acute pancreatitis observed within the first 72 hours; the same applies to poor candidates for surgery (see algorithm). In other cases, EUS may be proposed particularly if several days have elapsed between the onset of symptoms and treatment in order to verify CBD patency. In patients with persistent CBD stones, EUS can determine the size, location and number of stones, whether they are impacted or mobile, the diameter of the CBD and cystic ducts, type of the cystic duct implantation (normal or deep) and finally the state of the gallbladder (acute endosonographic severe cholecystitis with cholecysto-bulbar fistula is a contraindication to laparoscopic cholecystectomy). The above elements are helpful to the surgeon in selecting the best extraction strategy. If a cause other than stones is found at EUS such as cholangiocarcinoma, ampullary or pancreatic tumours, endosonographic loco-regional extension can also be performed [14].

- For patients at intermediate-risk, the most appropriate current strategy comprises preoperative EUS possibly followed by either endoscopic sphincterotomy during the same session in the event of CDB stones or laparoscopic extraction if the surgeon is skilled in this manner and in the absence of factors predictive of conversion to laparotomy (see algorithm).

<table>
<thead>
<tr>
<th>Author</th>
<th>Study design</th>
<th>No. patients</th>
<th>Frequency of choledocholithiasis</th>
<th>Sensitivity %</th>
<th>Specificity %</th>
<th>Diagnostic accuracy %</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amouyal, 1994 [5]</td>
<td>Prospective/Blind</td>
<td>62</td>
<td>32 (52 %)</td>
<td>97</td>
<td>100</td>
<td>98</td>
</tr>
<tr>
<td>Shim, 1995 [6]</td>
<td>Prospective/Blind</td>
<td>132</td>
<td>28 (21 %)</td>
<td>89</td>
<td>100</td>
<td>97</td>
</tr>
<tr>
<td>Palazzo, 1995 [7]</td>
<td>Retrospective/Blind</td>
<td>422</td>
<td>152 (36 %)</td>
<td>95</td>
<td>98</td>
<td>96</td>
</tr>
<tr>
<td>Prat, 1996 [8]</td>
<td>Prospective/Blind</td>
<td>119</td>
<td>78 (66 %)</td>
<td>93</td>
<td>97</td>
<td>95</td>
</tr>
<tr>
<td>Sugiyama, 1997 [9]</td>
<td>Prospective/Blind</td>
<td>142</td>
<td>51 (36 %)</td>
<td>96</td>
<td>100</td>
<td>99</td>
</tr>
<tr>
<td>Norton, 1997 [10]</td>
<td>Prospective/Blind</td>
<td>50</td>
<td>24 (48 %)</td>
<td>88</td>
<td>96</td>
<td>92</td>
</tr>
</tbody>
</table>
Table 2  Risk of presence of common bile duct (CBD) stones in patients with suspected choledocholithiasis according to clinical, biological and morphological criteria

<table>
<thead>
<tr>
<th>Chance of CBD stones</th>
<th>Clinical parameters</th>
<th>Biological parameters</th>
<th>CBD diameter</th>
</tr>
</thead>
<tbody>
<tr>
<td>Low risk</td>
<td>2 – 3%</td>
<td>no associated clinical history</td>
<td>normal</td>
</tr>
<tr>
<td>Intermediate risk</td>
<td>20 – 50%</td>
<td>acute ascending cholangitis pancreatitis</td>
<td>† ALP ≤ twice UPL*&lt;sup&gt;†&lt;/sup&gt;</td>
</tr>
<tr>
<td>High risk</td>
<td>50 – 80%</td>
<td>acute ascending cholangitis jaundice</td>
<td>† ALP &gt; twice UNL*&lt;sup&gt;†&lt;/sup&gt;</td>
</tr>
</tbody>
</table>

*UPL: the upper normal value
ALP: alkaline phosphatase; AST: aspartate transaminase; ALT: alanine transaminase

function (SOD), is impossible to differentiate on clinical, biochemical or evolutionary criteria.

Residual or recurrent lithiasis is potentially serious if not recognised and untreated due to the risk of ascending cholangitis or severe pancreatitis. It is therefore important to diagnose it when it is suspected. SOD on the other hand is different in that the majority of complications stem from diagnostic efforts using ERCP, especially if endoscopic sphincterotomy is performed [34, 35 – 37] (the latter of which is necessary in the event of the discovery of a dilated CBD in order avoid misdiagnosing small stones not seen at simple injection of contrast medium [38]) or using sphincter of Oddi manometry. In fact, in case of SOD, ERCP and manometry are accompanied by a serious risk of acute pancreatitis [34 – 37]. The paradox in this situation is that endoscopic sphincterotomy is the treatment of choice in terms of efficacy, morbidity and death rate with respect to residual or recurrent lithiasis [39], while this is an effective but also very dangerous treatment (about 20% of acute pancreatitis) in cases of SOD [34 – 37]. Thus, caution should be applied prior to endoscopic sphincterotomy where the diagnosis of residual lithiasis and SOD is not apparent. EUS is clearly the examination of choice in this delicate situation and its use appears even clearer in patients at high risk of SOD, i.e. in young subjects with narrow CBD and no evidence of ascending cholangitis.

![Fig. 5](image_url)  
*a. Microlithiasis (1 mm) in the neck of the gallbladder. b. Micro-lithiasis of the gallbladder with typical “stared sky” aspect.*

EUS after Cholecystectomy

Residual or recurrence lithiasis of the CBD following cholecystectomy occurs in 1 – 5% of cases [33]. In routine practice, such a situation is suspected when there is either biliary colic associated with transient abnormalities in the hepatic or pancreatic blood tests or persistent abnormalities in blood tests with or without a dilated CBD at trans-abdominal ultrasound. This situation is quite frequent in daily practice and is complicated by the fact that the main differential diagnosis, i.e. sphincter of Oddi dys-

![Fig. 6](image_url)  
*Fig. 6 Dilatation of the intra-pancreatic portion of the CBD (which measures 7 mm). Note that the common hepatic duct is dilated (CHD) as well as the remnant of the cystic duct.*

O’Toole D, Palazzo L. Choledocholithiasis – a practical... Endoscopy 2006; 38 (S1): S23 – S29
As regards MRCP, its role in this sub-group of patients with thin bile ducts is worthy of evaluation and prospective comparison with EUS (see above).

Asymptomatic dilatation of the common bile duct

Although in a routine clinical setting the significance of a dilated CBD in the absence of symptoms pertaining to biliary or pancreatic disease is extremely frequent, little research data is available on this subject. Several mechanisms may result in dilatation of the extra-hepatic bile ducts including strictly benign disorders — post cholecystectomy (Fig.6), dilatation secondary to certain drugs (opiates…) or incidental anomalous junction of the pancreatico-biliary duct (AUPBD) — where follow-up explorations are indeed not required. Indeed, although many experts felt that a large CBD diameter was physiological in the elderly and while the diameter increases significantly with age, 98% of all ducts remained below 6 to 7 mm, the commonly accepted upper range of normal, in a large prospective series of asymptomatic patients (n = 1018) aged 60 to 94 years (analysis performed using trans-abdominal US) [40]. However, a number of situations exist where “significant” pathologies results in an asymptomatic dilated CBD including asymptomatic choledocholithiasis, malignant and benign (e.g., sclerosing cholangitis) strictures and choledochal cysts. Indeed, asymptomatic choledocholithiasis has been estimated to be as high as 19% in some surgical series [41] — thus underlying the need for thorough CBD exploration in patients undergoing laparoscopic cholecystectomy (as discussed above). Recently, Kim et al. [42] studied 77 patients with an asymptomatic internal CBD diameter > 7 mm at US and without a definite causative lesion on the latter. Of these, 49 underwent ERCP and 28 underwent follow-up US or CT instead of ERCP. Patients with increased bilirubin or with a previous history of upper abdominal surgery including cholecystectomy were excluded. Follow-up examinations revealed: a) ERCP: no lesion in 20 patients (41%), jux-tapapillary duodenal diverticulum (JDD) in 11 (23%), benign stricture in ten (20%), distal CBD mass in two (4%), choledochal cyst in two (4%), anomalous junction of the pancreatico-biliary duct (AUPBD) in two (4%), and choledochal cyst with AUPBD in two (4%). There were no differences in age or in alkaline phosphatase or gamma-glutamyl transpeptidase levels between the patients who had causative lesions revealed at ERCP and those who did not; b) among the 28 patients who did not undergo ERCP, the CBD returned to normal in 12 and eight had no change in CBD diameter on follow-up US. Among eight patients who underwent CT, there were four with normal findings, one with JDD, and three with suspected choledochal cysts [42]. Thus a significant cause of biliary tract lesions in asymptomatic adults with dilatation of the CBD can be found and certain such as choledochal cysts require careful surveillance and preventive surgery [43]. Most often, a dilated CBD in such circumstances results from an incidental discovery at US or CT — performed for another unrelated reason. While these examinations in themselves can help in ruling out obvious causes (e.g., early malignant obstruction or a large asymptomatic stone) endosonography appears to be the method of choice as it capable of providing a diagnosis in almost all cases; In fact, EUS was found to provide an accurate explanation for CBD dilatation from an unexplained cause in 70 of the 76 patients (92%) [44].

Conclusions

Despite the development of MRCP and the laparoscopic extraction of CBD stones, the place of EUS in the diagnosis of CBD stones remains important. The examination combines the best performance and almost zero morbidity and unlike EUS for other indications, the results in relation to choledocholithiasis depend little on the experience of the operator. Its role in relation to other diagnostic techniques depends principally on the environment (experience of the surgeon and interventional endoscopist) and the circumstances of the diagnosis. The main advantages of EUS are its sensitivity and specificity even in patients with small calculi in a non-dilated CBD. In the future however, other imaging modalities may challenge EUS. The role of EUS versus that of ERCP has been correctly defined; a comparison with MRC needs to be evaluated prospectively in a controlled group of patients who pose serious frequent diagnostic dilemmas, i.e. those with a non-dilated CBD and small stones, because these are patients who represent difficult therapeutic problems in terms of feasibility for laparoscopic extraction and in terms of the potential morbidity of laparoscopic extraction and endoscopic sphincterotomy. Finally, when EUS is chosen as the imaging modality to identify CBD stones, it seems logical to perform ERCP during the same session to enable therapeutic extraction. Thus, training in both biliary EUS and therapeutic ERCP seems to be a promising goal for young endoscopists who want to specialize in interventional endoscopy.

References

3 Snady H, Cooperman A, Siegel J. Endoscopic ultrasound compared with computed tomography with ERCP in patients with obstructive jaundice or small peri-pancreatic mass. Gastrointest Endosc 1992; 38: 27–34
